A Phase 1/2, Multicenter, Open-Label, Dose-Escalation Study to Evaluate the Safety and Efficacy of Lenalidomide in Combination With Sunitinib in Subjects With Advanced or Metastatic Renal Cell Carcinoma
Phase of Trial: Phase I/II
Latest Information Update: 05 Jun 2017
At a glance
- Drugs Lenalidomide (Primary) ; Sunitinib
- Indications Renal cancer
- Focus Adverse reactions; Therapeutic Use
- Sponsors Celgene Corporation
- 10 Apr 2012 Additional lead trial investigator identified as reported by ClinicalTrials.gov.
- 10 Apr 2012 Actual end date (1 Oct 2011) added as reported by ClinicalTrials.gov.
- 28 Mar 2012 Status changed from recruiting to discontinued as reported by ClinicalTrials.gov.